Circulating Her-2/Neu Extracellular Domain in Breast Cancer Patients-Correlation with Prognosis and Clinicopathological Parameters Including Steroid Receptor, Her-2/Neu Receptor Coexpression
详细信息    查看全文
  • 作者:Marina Bari? ; Ana Kuli? ; Maja Sirotkovi?-Skerlev…
  • 关键词:HER ; 2/neu ECD ; Breast cancer ; Prognosis ; Steroid receptor/HER ; 2/neu receptor coexpression
  • 刊名:Pathology & Oncology Research
  • 出版年:2015
  • 出版时间:July 2015
  • 年:2015
  • 卷:21
  • 期:3
  • 页码:589-595
  • 全文大小:606 KB
  • 参考文献:1.Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mcguire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-82View Article PubMed
    2.Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN (2009) The HER-2 receptor and breast cancer: 10?years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 4:320-68View Article
    3.Suzuki M, Shigematsu H, Hiroshima K, Iizasa T, Nakatani Y, Minna JD et al (2005) Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36:1127-134View Article PubMed
    4.Zeng S, Yang Y, Tan Y, Lu C, Pan Y, Chen L et al (2012) ERBB2-induced inflammation in lung carcinogenesis. Mol Biol Rep 39:7911-917View Article PubMed
    5.Minner S, Jessen B, Stiedenroth L, Burandt E, K?llermann J, Mirlacher M et al (2010) Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 16:1553-560View Article PubMed
    6.Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003) Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the gynecologic oncology group. J Clin Oncol 21:283-90View Article PubMed
    7.Giuffrè G, Ieni A, Barresi V, Caruso RA, Tuccari G (2012) HER2 status in unusual histological variants of gastric adenocarcinomas. J Clin Pathol 65:237-41View Article PubMed
    8.Tsé C, Gauchez AS, Jacot W, Lamy PJ (2012) HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev 38:133-42View Article PubMed
    9.Sasso M, Bianchi F, Ciravolo V, Tagliabue E, Campiglio M (2011) HER2 splice variants and their relevance in breast cancer. J Nucleic Acids Investig 2:e9View Article
    10.Horwitz KB, Mcguire WL (1977) Progesterone and progesterone receptors in experimental breast cancer. Cancer Res 37:1733-738PubMed
    11.Bloom HJ, Richardson WW (1957) Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15?years. Br J Cancer 11(3):359-77View Article PubMed Central PubMed
    12.Carney WP, Neumann R, Lipton A, Leitzel K, Ali S, Price CP (2003) Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49:1579-598View Article PubMed
    13.Dresse M MD, Heinemann V, Kahlert S, Bauerfeind I, Nagel D, et al.. (2009) HER-2/neu in tissue and serum at time of primary breast cancer. J Clin Oncol Abstract #11500.
    14.Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Rüschoff J, Osamura RY et al (2009) Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients. J Clin Oncol 27:1694-705View Article PubMed
    15.Carney WP, Bernhardt D, Jasani B (2013) Circulating HER2 extracellular domain: a specific and quantitative biomarker of prognostic value in all breast cancer patients? Biomark Cancer 5:31-9View Article PubMed Central PubMed
    16.Thriveni K, Deshmane V, Bapsy PP, Krishnamoorthy L, Ramaswamy G (2007) Clinical utility of serum human epidermal receptor-2/neu detection in breast cancer patients. Indian J Med Res 125:137-42PubMed
    17.Garoufali A, Kyriakou F, Kountourakis P, Yioti I, Malliou S, Nikaki A et al (2008) Extracellular domain of HER2: a useful marker for the initial workup and follow-up of HER2-positive breast cancer. J BUON 13:409-13PubMed
    18.Pallud C, Guinebretiere JM, Guepratte S, Hacene K, Neumann R, Carney W et al (2005) Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours. Anticancer Res 25:1433-440PubMed
    19.Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras JL, Pichon MF (2004) Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. Int J Biol Markers 19:14-2PubMed
    20.Kong Y, Dai S, Xie X, Xiao X, Lv N, Guo J et al (2012) High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients. J Cancer Res Clin Oncol 138:275-84View Article PubMed
    21.Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744-749PubMed
    22.Codony-Servat J, Albanell J, Lopez-Talavera J, Arribas J, Baselga J (1999) Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res 59:1196-201PubMed
    23.Quaranta M, Daniele A, Coviello M,
  • 作者单位:Marina Bari? (1)
    Ana Kuli? (2)
    Maja Sirotkovi?-Skerlev (2)
    Natalija Dedi? Plaveti? (1) (2)
    Marina Vidovi? (1)
    Gordana Horvati?-Herceg (3)
    Damir Vrbanec (1) (2)

    1. Department of Medical Oncology, Division of Oncology, University Hospital Center Zagreb and Zagreb Medical School, Ki?pati?eva 12, HR- 10 000, Zagreb, Croatia
    2. Department of Pathophysiology, Division of Oncology, University Hospital Center Zagreb and Zagreb Medical School, Zagreb, Croatia
    3. Clinical Department of Nuclear Medicine and Radiation Protection, University Hospital Center Zagreb, Zagreb, Croatia
  • 刊物主题:Cancer Research; Oncology; Pathology; Immunology; Biomedicine general;
  • 出版者:Springer Netherlands
  • ISSN:1532-2807
文摘

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700